source
- Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 failEvommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.
- Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancerSolstice Oncology, a biotech startup focused on immunotherapy, announced it has raised $225 million in a Series A financing round. The funding will support development of its lead candidate, a CTL…